Blog August 8, 2022
In July, the Institute for Clinical and Economic Review (ICER) published its final evidence report for bluebird bio’s Zynteglo (betibeglogene autotemcel or “beti-cel”) for the treatment of beta thalassemia, a rare, debilitating blood disorder.
Blog August 1, 2022
Read on to find out what our behavioral science experts think of Apple’s latest report, and the opportunity to amplify the role of HCPs.
Blog July 20, 2022
Drug pricing legislation continues to forge ahead with a significant healthcare proposal back in play.
Blog July 20, 2022
On July 1st, The Centers for Medicare & Medicaid Services, through its Center for Medicare & Medicaid Innovation (CMMI), announced its newest voluntary oncology payment model, Enhancing Oncology Model (EOM).
Blog July 7, 2022
Patients with learning disabilities, low literacy levels, poor health literacy, and nonnative language skills are often excluded from the routine health monitoring that patient reported outcomes (PROs) can provide. Learn why, and what we can do to shift this trajectory.
Blog July 7, 2022
While significant strides have been made to improve PRO inclusion in clinical trials and routine clinical practice, strategies to include underserved groups are in short supply.
Blog July 7, 2022
Real world evidence: what it is, what it is important, and what it means for healthcare communicators.
Blog June 23, 2022
Suzanne Goss, Executive Vice President of Brand Strategy at Syneos Health Communications, shares her takeaways from the 2022 ASCO convention, and sheds light on the questions we need to ask ourselves as we move toward more equitable care.
Blog June 23, 2022
It’s estimated that 37% of the world’s population are digitally excluded. Learn more about the digital divide, how it relates to patient-reported outcomes, and how we're addressing these issues at Syneos Health Communications.
Blog June 15, 2022
Hear from a few members from our Syneos Health DEI Advisory Council on how DE&I can play a role in the mental health and wellbeing of your employees.
Blog June 15, 2022
CMS has recently finalized a rule that aims to save beneficiaries and pharmaceutical manufactures money. The rule will require that pharmacy concessions be passed through to Medicare beneficiaries at the point of sale and will go into effect in 2024.
Blog June 14, 2022
While federal drug pricing reform in the Build Back Better Act (BBBA) is stalled at the Senate, states are taking the issue into their own hands.
Blog June 2, 2022
The European Federation of Pharmaceutical Industries and Association (EFPIA) Waiting to Access Innovative Therapies (W.A.I.T.) Indicator Survey has been released. The survey examines access to 160 innovative medicines over a 5-year period (2017-2021).
Blog May 25, 2022
As psychedelics gain more attention as treatments for certain mental health disorders, here are a few notes on what the pharmaceutical industry can expect.
Blog May 25, 2022
Syneos Health Communications' in-house wellness expert Leslie Archer tells us how corporate wellness initiatives are integral to a healthy employee, and a healthy company overall.
Blog May 23, 2022
There’s no hard-and-fast formula for how to react (or not react) on social media when a crisis or issue arises. This article shares a few considerations to help guide your decision-making process.
Blog May 12, 2022
While pharmaceutical manufacturers need to continue engaging with the broader healthcare system to help address healthcare disparities in the long term, there is action they can take now.
Blog May 10, 2022
The Institute for Clinical and Economic Review (ICER) recently published the white paper “The Next Generation of Rare Disease Drug Policy: Ensuring Both Innovation and Affordability.” Read on to learn what it means for science manufacturers.
Blog April 28, 2022
Awards matter - to clients, to talent, and to the success of the healthcare communications industry. Hear why from PR expert Elizabeth Stelzer.
Blog April 28, 2022
What the CMS National Coverage Decision Means for the Life Science Industry
Blog April 28, 2022
For many patients, receiving care right away is of vital importance. This post discusses how prior authorization for certain therapies can slow that process down, placing burden on patients and providers, and ultimately, slowing down the treatment process.
Blog April 11, 2022
A strategic marketing communications program that doesn’t include a DE&I lens isn’t strategic. Syneos Health Communications is raising the bar internally and for clients by convening the Syneos DEI Advisory Council to provide insights, consultation, and expertise.
Blog March 29, 2022
COVID-19 has changed the way we think, live, and work. Now, it's important to pause and consider how we continue to evolve, what we retain from the first years of the pandemic, and how we rectify the issues that it helped bring to light.
Blog March 24, 2022
Financial toxicity decreases cancer patients’ quality of life – but early identification and strategic planning can mitigate the impact overall.
Blog March 18, 2022
Patients and healthcare providers are faced with an overwhelming landscape of over-complication, tension, and red tape. We should approach creative brand expression with this in mind, prioritizing clarity in order to remove unnecessary friction around behavior change.
Blog March 9, 2022
We kicked off our series about behavior-changing creative with a few thoughts on authenticity. Next, we’re focusing on bravery. We asked Syneos Health Communications creative leads about the role of bravery in creative expression.
Blog March 3, 2022
For this series, we are focusing on what it takes for creative work to inspire behavior change, which is even more critical when trying to get someone to do something for their benefit.
Blog February 25, 2022
There’s incredible power of a program that is shaped–from beginning to end–by voices from within a community. SPACES showed the world how a small, determined and passionate group of people could work together to change societal views of disability.
Blog February 24, 2022
Collaboration between advocacy groups and the healthcare industry can lead to better treatments, more engaged relationships and better quality of care.
Blog February 21, 2022
Oncologists want to see themselves as enabling both patient and drug success. Whether it is through advertising, or public relations, or medical education – it may be imperative to keep them in the picture in order to earn their interest and engagement with your treatment.
Already have a RSS feed reader?
